Feedback

Merck's antiviral pill reduces hospitalization of Covid patients

Source : 112 Ukraine

The companies plan to seek emergency authorization for the antiviral Covid treatment after the medicine showed “compelling results” in clinical trials
14:59, 2 October 2021

Open source

US pharmaceutical companies Merck and Ridgeback Biotherapeutics have developed a drug that reduces the risk of hospitalization or death by around 50% for patients with mild or moderate cases of Covid-19. It was reported by Nació Digital.

The companies plan to seek emergency authorization for the antiviral Covid treatment after the medicine showed “compelling results” in clinical trials.

The drug, molnupiravir, is administered orally and works by inhibiting the replication of the coronavirus inside the body.

An interim analysis of a phase 3 study found that 7.3% of patients treated with molnupiravir were hospitalized within 29 days. Of the patients who received a placebo, 14.1% were hospitalized or died by day 29. No deaths were reported in patients who were given molnupiravir within the 29-day period, while eight deaths were reported in placebo-treated patients.

Meanwhile, US-made Bamlanivimab and Etesevimab, the new drugs from Covid-19 are supposed to be delivered in all regions of Ukraine by the end of the week.

The medications are produced in the USA. The Ukrainian Embassy in this country sent the batch of these as humanitarian cargo.

Bamlanivimab and Etesevimab treat the coronarivus thanks to the action of monoclonal antibodies. Such medications can be recommended for patients who don't need any oxygen supplies but still belong to the group of high risk.

Related: 11,809 new Covid-19 cases observed in Ukraine

Topics:
Система Orphus

If you find an error, highlight the desired text and press Ctrl + Enter, to tell about it

Comments
see more